Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Sci Rep ; 14(1): 11533, 2024 05 21.
Article de Anglais | MEDLINE | ID: mdl-38773170

RÉSUMÉ

Tauopathies, including Alzheimer's disease and Frontotemporal Dementia, are debilitating neurodegenerative disorders marked by cognitive decline. Despite extensive research, achieving effective treatments and significant symptom management remains challenging. Accurate diagnosis is crucial for developing effective therapeutic strategies, with hyperphosphorylated protein units and tau oligomers serving as reliable biomarkers for these conditions. This study introduces a novel approach using nanotechnology to enhance the diagnostic process for tauopathies. We developed humanized ferritin nanocages, a novel nanoscale delivery system, designed to encapsulate and transport a tau-specific fluorophore, BT1, into human retinal cells for detecting neurofibrillary tangles in retinal tissue, a key marker of tauopathies. The delivery of BT1 into living cells was successfully achieved through these nanocages, demonstrating efficient encapsulation and delivery into retinal cells derived from human induced pluripotent stem cells. Our experiments confirmed the colocalization of BT1 with pathological forms of tau in living retinal cells, highlighting the method's potential in identifying tauopathies. Using ferritin nanocages for BT1 delivery represents a significant contribution to nanobiotechnology, particularly in neurodegenerative disease diagnostics. This method offers a promising tool for the early detection of tau tangles in retinal tissue, with significant implications for improving the diagnosis and management of tauopathies. This study exemplifies the integration of nanotechnology with biomedical science, expanding the frontiers of nanomedicine and diagnostic techniques.


Sujet(s)
Ferritines , Rétine , Tauopathies , Protéines tau , Humains , Protéines tau/métabolisme , Ferritines/métabolisme , Rétine/métabolisme , Rétine/anatomopathologie , Tauopathies/métabolisme , Tauopathies/anatomopathologie , Tauopathies/diagnostic , Cellules souches pluripotentes induites/métabolisme , Enchevêtrements neurofibrillaires/métabolisme , Enchevêtrements neurofibrillaires/anatomopathologie
2.
Front Aging Neurosci ; 15: 1110520, 2023.
Article de Anglais | MEDLINE | ID: mdl-37009460

RÉSUMÉ

Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neuron function. Although ophthalmic deficits are not considered a classic symptom of ALS, recent studies suggest that changes in retinal cells, similar to those in the spinal cord motor neurons, have been observed in postmortem human tissues and animal models. Methods: In this study, we examined by immunofluorescence analysis the retinal cell layers of sporadic ALS patients in post-mortem retinal slices. We evaluated the presence of cytoplasmic TDP-43 and SQSTM1/p62 aggregates, activation of the apoptotic pathway, and microglia and astrocytes reactivity. Results: We found in the retinal ganglion cell layer of ALS patients the increase of mislocalized TDP-43, SQSTM1/p62 aggregates, activation of cleaved caspase-3, and microglia density, suggesting that retinal changes can be used as an additional diagnostic tool for ALS. Discussion: The retina is considered part of the central nervous system, and neurodegenerative changes in the brain may be accompanied by structural and possibly functional changes in the neuroretina and ocular vasculature. Therefore, using in vivo retinal biomarkers as an additional diagnostic tool for ALS may provide an opportunity to longitudinally monitor individuals and therapies over time in a noninvasive and cost-effective manner.

3.
Life (Basel) ; 12(11)2022 Nov 14.
Article de Anglais | MEDLINE | ID: mdl-36431019

RÉSUMÉ

Maintaining the excitability of neurons and circuits is fundamental for healthy brain functions. The global compensatory increase in excitatory synaptic strength, in response to decreased activity, is one of the main homeostatic mechanisms responsible for such regulation. This type of plasticity has been extensively characterized in rodents in vivo and in vitro, but few data exist on human neurons maturation. We have generated an in vitro cortical model system, based on differentiated human-induced pluripotent stem cells, chronically treated with tetrodotoxin, to investigate homeostatic plasticity at different developmental stages. Our findings highlight the presence of homeostatic plasticity in human cortical networks and show that the changes in synaptic strength are due to both pre- and post-synaptic mechanisms. Pre-synaptic plasticity involves the potentiation of neurotransmitter release machinery, associated to an increase in synaptic vesicle proteins expression. At the post-synaptic level, we report an increase in the expression of post-synaptic density proteins, involved in glutamatergic receptor anchoring. These results extend our understanding of neuronal homeostasis and reveal the developmental regulation of its expression in human cortical networks. Since induced pluripotent stem cell-derived neurons can be obtained from patients with neurodevelopmental and neurodegenerative diseases, our platform offers a versatile model for assessing human neural plasticity under physiological and pathological conditions.

4.
Nat Commun ; 12(1): 3495, 2021 06 09.
Article de Anglais | MEDLINE | ID: mdl-34108486

RÉSUMÉ

Lysosomal storage disorders characterized by altered metabolism of heparan sulfate, including Mucopolysaccharidosis (MPS) III and MPS-II, exhibit lysosomal dysfunctions leading to neurodegeneration and dementia in children. In lysosomal storage disorders, dementia is preceded by severe and therapy-resistant autistic-like symptoms of unknown cause. Using mouse and cellular models of MPS-IIIA, we discovered that autistic-like behaviours are due to increased proliferation of mesencephalic dopamine neurons originating during embryogenesis, which is not due to lysosomal dysfunction, but to altered HS function. Hyperdopaminergia and autistic-like behaviours are corrected by the dopamine D1-like receptor antagonist SCH-23390, providing a potential alternative strategy to the D2-like antagonist haloperidol that has only minimal therapeutic effects in MPS-IIIA. These findings identify embryonic dopaminergic neurodevelopmental defects due to altered function of HS leading to autistic-like behaviours in MPS-II and MPS-IIIA and support evidence showing that altered HS-related gene function is causative of autism.


Sujet(s)
Trouble du spectre autistique/métabolisme , Dopamine/métabolisme , Héparitine sulfate/métabolisme , Maladies lysosomiales/métabolisme , Animaux , Trouble du spectre autistique/traitement médicamenteux , Trouble du spectre autistique/anatomopathologie , Benzazépines/usage thérapeutique , Prolifération cellulaire , Cellules cultivées , Modèles animaux de maladie humaine , Antagonistes de la dopamine/usage thérapeutique , Neurones dopaminergiques/effets des médicaments et des substances chimiques , Neurones dopaminergiques/métabolisme , Neurones dopaminergiques/anatomopathologie , Héparitine sulfate/pharmacologie , Maladies lysosomiales/traitement médicamenteux , Maladies lysosomiales/anatomopathologie , Mésencéphale/effets des médicaments et des substances chimiques , Mésencéphale/embryologie , Mésencéphale/anatomopathologie , Souris , Mucopolysaccharidose de type III/traitement médicamenteux , Mucopolysaccharidose de type III/métabolisme , Mucopolysaccharidose de type III/anatomopathologie , Récepteur dopamine D1/antagonistes et inhibiteurs , Récepteur dopamine D1/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...